To identify PTPN22 inhibitors, we leveraged traditional Chinese medicine monomers, a rich source of bioactive compounds, screening for antitumor agents with anti-inflammatory properties in response to the rapid advancement of RCC immunotherapy. The gene discussed is PTPN22; the disease is renal cell carcinoma.